Literature DB >> 10397482

Perceived benefits of and barriers to participation in a phase I/II colon cancer chemoprevention trial.

K S Hudmon1, R R Love, R M Chamberlain.   

Abstract

METHOD: A questionnaire was administered to 42 subjects completing a one-year cancer chemoprevention trial (response rate = 69%, n = 29). The questionnaire assessed subjects' 1) previous study participation, 2) perceived benefits/barriers of participation, 3) likelihood of participating in future trials, 4) willingness to pay out-of-pocket expenses for trial participation, and 5) interest in post-trial continuation of the drug.
RESULTS: The most highly rated benefits of trial participation were the possibility of reducing one's chance of getting cancer and the possibility of preventing others from getting cancer in the future. Barriers considered to be the most troublesome were billing problems and having colonoscopies done. Only 29% would have joined the trial had they been required to pay for trial-related costs.
CONCLUSION: Results of this study may be used to educate potential participants about the benefits of/barriers to trial participation. Additionally, by learning from the experiences of trial participants, investigators can improve the execution of clinical trials, increasing participant satisfaction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397482     DOI: 10.1080/08858199909528585

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  2 in total

1.  Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer.

Authors:  Nagi B Kumar; Gwendolyn P Quinn; Mark G Alexandrow; Jhanelle Gray; Michael Schell; Steve Sutton; Eric B Haura
Journal:  J Clin Trials       Date:  2014-09

2.  Cancer prone persons. A randomized screening trial based on colonoscopy: background, design and recruitment.

Authors:  F Eisinger; J P Giordanella; A Brigand; R Didelot; D Jacques; G Schenowitz; C Julian-Reynier; J F Seitz; H Sobol; J Faivre; H Allemand
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.